ITF2357 (Givinostat, Gavinostat) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.The IC50 vale for maize HDAC preparations HD2, HD-1B and HD-1A are 10, 7.5 and 16 nM respectively. ITF2357 (Givinostat, Gavinostat) inhibits class I and class II histone deacetylases (HDACs) and several pro-inflammatory cytokines.This reduces expression of tumour necrosis factor (TNF), interleukin 1α and β, and interleukin 6. ITF2357 (Givinostat,Gavinostat) also has activity against cells expressing JAK (2V617F), a mutated form of the janus kinase 2 (JAK2) enzyme that is implicated in the pathophysiology of many myeloproliferative diseases, including polycythaemia vera.
|Cell lines||Purified monocytes|
|Preparation method||Caspase 3/7 Determinations
Monocytes were isolated from freshly obtained unfractionated PBMCs by anti-CD14–labeled magnetic beads (CD14 MicroBeads, Miltenyi Biotec, Bergisch Gladbach, Germany) and incubated at 50,000 cells/well in flat-bottom 96-well plates in the presence of increasing concentrations of ITF2357 for 1 h. Thereafter, LPS (10 ng/mL) was added for an additional 24-h incubation. The activity of caspase 3/7 was then determined by Apo-ONE Homogeneous Caspase-3/7 Assay (Promega), and the amount of fluorescence was detected by fluorimetric plate reader (Victor-2; Perkin Elmer).
|Concentrations||0~ 1000 nM|
|Incubation time||24 h|
|Animal models||ConA-induced hepatitis in BALB/C mice|
|Formulation||One milligram of ITF2357 was added to 1 mL water and heated to 90° C until dissolved|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Source||Int J Cancer (2014). Figure 3. ITF2357|
|Cell Lines||SU-DHL-4 and DOHH-2 cells|
|Incubation Time||24 h|
|Results||The cytostatic and cytotoxic effects of ITF2357 appeared instead to be more closely associated with c-Myc reduction|
Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).
Furlan A et al. Mol Med. 2011 May-Jun;17(5-6):353-62. PMID: 21365126.
Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.
Joosten LA et al. Mol Med. 2011 May-Jun;17(5-6):391-6. PMID: 21327299.
Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes.
Bodar EJ et al. Mol Med. 2011 May-Jun;17(5-6):363-8. PMID: 21274502.
The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.
Lewis EC et al. Mol Med. 2011 May-Jun;17(5-6):369-77. PMID: 21193899.
ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study.
Galimberti S et al. Anticancer Res. 2010 Nov;30(11):4525-35. PMID: 21115902.
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo.
Leoni F, et al. Mol Med. 2005 Jan-Dec;11(1-12):1-15. PMID: 16557334.
|Related HDAC Products|
Chidamide is a low nanomolar inhibitor of HDAC1, 2, 3, and 10, the HDAC isotypes well documented to be associated with the malignant phenotype with IC50 values of 95, 160, 67, 78 nM for HDAC1, 2, 3, 10 respectively.
TMP195 is a selective, first-in-class, class IIa HDAC inhibitor with IC50 of 300 nM in cell-based class IIa HDAC assays.
WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM.
EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.
Citarinostat (ACY-241) is an orally available selective HDAC6 inhibitor with IC50 of 2.6 nM and 46 nM for HDAC6 and HDAC3, respectively. It has 13 to 18-fold selectivity towards HDAC6 in comparison to HDAC1-3.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.